Financial Performance Highlights - Q1 FY27
- Consolidated revenue of ₹1,940.5 crore, representing 38.2% YoY growth (40.0% on like-for-like basis)
- Organic revenue growth of 17.8% YoY (19.6% on like-for-like basis)
- Inorganic growth of 20.4% entirely due to calendarisation
- Gross margin improved by 147 basis points YoY to 11.4%
- EBITDA margin improved by 143 basis points YoY to 5.0%
- PAT margin at 2.7%
- Profit After Tax (to owners) of ₹38.2 crore, up 37% YoY
- Basic EPS of ₹8.77 and Diluted EPS of ₹8.76
Operational Metrics
- Net Working Capital days improved to 61 days from 66 days in Q1FY26
- ROCE improved to 21.0% from 11.5% in Q1FY26
- ROE improved to 20.4% from 9.0% in Q1FY26
- No new acquisitions during the quarter
Management Commentary
Prabhat Agrawal, Promoter, MD and CEO stated the company started FY27 on strong footing with confidence in delivering on guidance. The company consciously exited certain low-margin businesses.
Business Overview
- Among top three healthcare products distributors in India
- Pan-India presence through 138 warehouses in ~45 cities across 19+ states & Union Territories
- Track record of 51 acquisitions since inception
- Offers both demand fulfilment & generation solutions to healthcare product manufacturers
- FY27 MedTech revenue expected to cross ₹1,000 crore
Financial Position (as of March 31, 2026)
- Total Assets: ₹3,600.2 crore
- Shareholders' funds: ₹1,752.5 crore
- Equity Share capital: ₹43.5 crore
- Non-current assets: ₹1,091.8 crore (including Goodwill of ₹749.1 crore)
- Current assets: ₹2,508.4 crore (including Inventories ₹841.7 crore, Trade receivables ₹1,212.4 crore)
- Current liabilities: ₹1,587.6 crore
Leadership Team
Key management includes Prabhat Agrawal (Promoter, MD and CEO), Prem Sethi (Promoter, Whole-time Director and COO), Balakrishnan Natesan Kaushik (Group CFO), and other senior executives across growth, procurement, sales, and legal functions.
Additional Information
The presentation will be available on company website at www.enterohealthcare.com.